Entheon announces an agreement for the purpose of conducting a Phase 1 clinical trial.
Entheon announces an agreement for the purpose of conducting a Phase 1 clinical trial.
Entheon adds a German listing to its original CSE listing.
MindMed's CAD$25-million bought deal financing becomes a $30 million financing -- the same day.
MindMed's most recent financing is at nearly double where it priced units just 6 weeks earlier.
MindMed launches its digital medical division.
Novamind has closed on double its original target (CAD$5 million). Preparing to commence trading on the CSE (symbol "NM").
With ATAI eying a Spring 2021 IPO, it announces a $125 million private equity financing for Series C.
Revive Therapeutics and PharmaTher are teaming up to research the potential of psilocybin as a cancer treatment.
Including its new financing, Mind Cure currently has in excess of CAD$5 million in cash.
Field Trip announces a new clinics-based research program, beginning with psychedelic therapies for military veterans.
Psychedelics Have Proven Potential To Disrupt Entire Mental Healthcare Industry
Get Your Guide To “Ground Floor” Opportunity In Psychedelic Stocks Now